Comparison of thrice-daily lispro 50/50 vs thrice-daily lispro in combination with sulfonylurea as initial insulin therapy for type 2 diabetes

Keiko Yamashiro¹, Fuki Ikeda¹, Yoshio Fujitani¹,², Hirotaka Watada¹, Ryuoz Kawamori²,³, Takahisa Hirose¹,²,³*

ABSTRACT

Aims/Introduction: Basal–bolus intensive insulin therapy has been believed to achieve the glycemic control, but is also complicated as a result of the number of injections required and the type of insulin. This study compared the effect of thrice-daily lispro 50/50 (prandial premixed therapy [PPT]) with thrice daily lispro given in combination with sulfonylureas (prandial bolus therapy with sulfonylurea [PBTS]) as initial insulin therapy for type 2 diabetes.

Materials and Methods: This 24-week, observational, parallel trial comprised a 12-week screening period and a 24-week intervention period for 31 diabetes patients who were poorly controlled with submaximal sulfonylurea. At the start of the intervention period, we commenced thrice-daily insulin injections and divided the 31 patients into either lispro 50/50 with discontinuation of sulfonylurea (PPT, n = 15) or lispro added to sulfonylurea (PBTS, n = 16). The same dose-adjustment algorithm was used for analyzing both groups; HbA1c, plasma glucose, insulin daily dose, bodyweight and number of hypoglycemic episodes were evaluated.

Results: At the end of the study, HbA1c was significantly improved in both groups (P < 0.00001), but no difference was apparent between the groups. The daily doses of PPT were more than those of PBTS, albeit the difference was statistically insignificant (P = 0.051). There were significantly fewer hypoglycemic episodes encountered with PPT than with PBTS.

Conclusions: Thrice-daily injections of lispro 50/50 provide an effective and safe regimen as initial insulin therapy for type 2 diabetes. (J Diabetes Invest, doi: 10.1111/j.2040-1124.2010.00025.x, 2010)

KEY WORDS: Insulin lispro, Mid-mix insulin, Hypoglycemia

INTRODUCTION

The guidelines for treatment of type 2 diabetes recommend initiating insulin therapy when HbA1c reaches 7.01–7.5%² and above, regardless of lifestyle modification and use of oral antidiabetic drugs (OAD). Most type 2 diabetes patients eventually require insulin therapy³, which is the most effective strategy for lowering hyperglycemia, has no maximal dose as for OAD and can improve any value of HbA1c to, or close to, the therapeutic goal when used appropriately⁴.

When we initiate insulin therapy in patients previously uncontrolled by maximal or submaximal OAD, we use basal insulin first⁴-⁸. However, this once-daily basal insulin therapy often does not achieve a high treat-to-target rate. Hence, we have also used premixed insulin twice daily, preprandial or basal–bolus intensive insulin therapy. It has been reported that at least preprandial or basal–bolus intensive insulin therapy can achieve a high treat-to-target rate⁹. However, the effectiveness of premix twice daily, in particular low mix, is controversial, resulting in the non-recommendation of these insulin therapies during dose adjustments, except in cases where the proportion of rapid- and intermediate-acting insulins is similar to the fixed proportions available¹⁰,¹¹. Unlike the low-mix insulin, insulin replacement therapy at a 50/50 ratio (mid-mix) with each meal would mimic physiological insulin secretion more closely than once-daily basal insulin treatment¹²-¹⁵. Furthermore, it has been reported that mid-mix thrice daily treatment achieved the target HbA1c value of <7.0% more than prandial bolus insulin therapy without sulfonylurea¹³. Both of these treatments require the same number of injections (thrice daily) and a single type of insulin. We have reported previously that continuation of sulfonylureas after switching to insulin therapy (low-mix twice daily) provides a better chance of strict glycemic control with a lower daily dose of insulin than the discontinuation of sulfonylureas¹⁶. These findings led us to expect a possible advantage in the addition of sulfonylurea to thrice-daily lispro. In these backgrounds, we compare the effects and safety of thrice-daily mid-mix insulin (lispro 50/50) with thrice-daily lispro combined with sulfonylureas as the initial insulin therapy for type 2 diabetes.
SUBJECTS AND METHODS

Subjects
We recruited patients who had type 2 diabetes for at least 12 months and who fulfilled the following criteria: (i) had been treated with maximally or submaximally tolerated doses of sulfonylureas along with or without biguanides and/or alpha-glucosidase inhibitors for at least 12 weeks; (ii) were 20–75 years-of-age; (iii) body mass index (weight in kilograms divided by the square of height in metres) ≤ 30 kg/m²; and (iv) HbA1c > 7.5% and on a stable diabetes therapy regimen of at least 12-week duration. All patients were insulin-naïve and outpatients. Patients were excluded if they had any of the following: (i) concomitant chronic disease including anaemia (hemoglobin £ 11.0 g/dL); (ii) kidney disease (plasma creatinine >1.50 mg/dL); (iii) liver pathology (AST > 80 IU/L or ALT > 80 IU/L); (iv) cardiovascular disease; (v) a recent acute illness; (vi) been treated with glitazone within the previous 24 weeks; (vii) proliferative diabetic retinopathy; (viii) been treated with steroids; or (ix) suspected or confirmed to be pregnant. All patients provided informed consent and confirmed their willingness to inject insulin and carry out glucose self-monitoring. The study protocol was approved by the ethics review committee of Juntendo University Hospital, Tokyo, Japan. The study was carried out in accordance with the ethics principles stated in the Declaration of Helsinki.

Study design, insulin initiation and titration
The present study was an open-label, multicentre, observational, parallel study to compare the effect of thrice-daily lispro 50/50 with thrice daily lispro combined with sulfonylurea as the initial insulin therapy for type 2 diabetes. The study consisted of an initial 12-week screening period followed by a 24-week intervention period (Figure 1). Patients visited the clinic every 4 weeks during the study. After the 12-week screening period, we commenced thrice-daily insulin injections and divided the 31 patients by turns into either lispro 50/50 with no sulfonylurea (prandial premixed therapy [PPT], n = 15) or lispro plus sulfonylurea (prandial bolus therapy with sulfonylurea [PBTS], n = 16). Patients were allowed to continue biguanides and/or alpha-glucosidase inhibitors, but were prohibited from changing medications during the study. The initiation dose was 4 units before each meal (12 units per day) for PPT and 3 units before each meal (9 units per day) for PBTS. The sulfonylureas previously prescribed were continued for PBTS, although the dose was decreased to 40 mg for gliclazide, 1 mg for glimepiride, and 2.5 mg for glibenclamide regardless of the dose used in previous therapy, and these doses were not changed during this study. The dose of sulfonylurea at baseline and at 24 weeks, which is shown in Table 1, was indicated as glimepiride. For the conversion of drugs, 40 mg of gliclazide was converted into 1 mg of glimepiride and 2.5 mg of glibenclamide was converted into 2 mg of glimepiride. Baseline uses of sulfonylurea were glimepiride for six patients, glibenclamide for nine patients and gliclazide for one patient in the PPT group. In the PBTS group, baseline uses of sulfonylurea were glimepiride for eight patients, glibenclamide for three patients and gliclazide for four patients.

We adjusted the doses of both types of insulin at breakfast according to blood glucose level of before lunch, those of lunch according to that of before dinner, and those of dinner according to that of bedtime. The same dose-adjustment algorithm was used in both groups (Figure 1). Basal insulin (glargine) could be added in patients on thrice daily PBTS in case fasting
Statistical analysis
All data are expressed as mean ± SD unless otherwise indicated. To compare the parameters in each group, one-way repeated measurement analysis of variance (ANOVA) was carried out using Bonferroni’s post-hoc test. To compare the change of HbA1c from baseline, paired t-test was carried out. The non-paired t-test was used to compare between-group differences. The mean rates of hypoglycemia were compared using the Mann–Whitney U test. A P value <0.05 was considered statistically significant.

RESULTS
A total of 37 patients were enrolled in the present study. Six patients (16%) dropped out during the screening phase (two showed improvement of glycemic control by less than 7.5% as measured by HbA1c during the screening period, three changed hospitals, and one was lost to follow-up). A total of 31 patients were finally enrolled and divided by turns into the two treatment groups: the PPT group (n = 15) and the PBTS group (n = 16). At 0 weeks, the demographic and clinical characteristics were comparable between the two groups (Table 1).

There was no difference in HbA1c between the two groups at 0 weeks. After the 24-week treatment, HbA1c values decreased from 10.3 ± 2.2% to 6.8 ± 0.9% in the PBTS group and from 9.2 ± 1.4% to 6.8 ± 1.0% in PPT patients (Figure 2). HbA1c values significantly improved from week 0 to week 24 in both groups (P < 0.00001). At the end of the study, 67% of PPT patients and 69% of PBTS patients achieved the target HbA1c value of <7.0%. Plasma glucose before breakfast improved in both of the groups, with significant differences between the baseline and 24-week results (PPT 207.8 ± 33.4 mg/dL to 142.7 ± 22.1 mg/dL, P < 0.0005; PBTS 178.1 ± 39.1 mg/dL to 132.1 ± 43.8 mg/dL, P < 0.0005).

The daily insulin doses for PPT patients (0.33 ± 0.11 U/kg per day) were larger than those for PBTS patients (0.25 ± 0.09 U/kg per day), although the difference was statistically insignificant (P = 0.051) by the end of the study. Basal insulin was applied to 3 of 16 patients in the PBTS group, because their fasting plasma glucose level was suspended at more
than 140 mg/dL after postprandial injections of insulin lispro. Bodyweight did not change throughout the study in the PBTS patients (58.5–59.1 kg), the PPT group showed statistically significant differences (61.2–63.3 kg, P < 0.05) at the end of the study.

No major hypoglycemic episodes or adverse events were observed in either group, although there were significantly more minor hypoglycemic episodes per person per year in PBTS than in PPT patients (PPT 0.60 ± 1.03, PBTS 4.48 ± 7.67, P = 0.03).

**DISCUSSION**

In the present study, we compared the effect of thrice-daily mid-mixed insulin lispro 50/50 (prandial premixed therapy [PPT]) with thrice daily lispro given in combination with sulfonylurea (prandial bolus therapy with sulfonylurea [PBTS]) as initial insulin therapy for type 2 diabetes. This trial showed that both PPT and PBTS significantly reduced HbA1c levels compared with baseline, but that the number of hypoglycemic episodes with PPT was significantly fewer than with PBTS.

The clinical value of PPT with mid-mixed insulin compared with basal insulin therapy has been shown in several studies12–15. In contrast, Rosenstock et al. reported that PPT had no benefit over basal bolus therapy17. However, these investigators also concluded that findings on HbA1c reduction (8.8–6.95%), percentage of patients achieving HbA1c targets (54% with A1c < 7.0%), hypoglycemia and the number of injections required should be considered on a case-by-case basis in the decision-making process of initiating insulin therapy in type 2 diabetes.

After the 24-week treatment, HbA1c values improved remarkably in both groups from week 0 onward. At the end of the study, 67% of PPT patients and 69% of the PBTS patients had achieved the target HbA1c value of <7.0%. The only difference observed between the PPT and PBTS groups was frequency of hypoglycemic episodes. Holman et al. also reported a high frequency of hypoglycemia in PBTS patients in the first phase of a 4-T study5. These authors compared add-on thrice-daily prandial rapid-acting insulin, twice-daily biphasic insulin, and once-daily (twice-daily if needed) basal insulin to maximally tolerated dose of sulfonylureas (and metformin)9. Similar HbA1c values were observed in the groups receiving thrice-daily prandial rapid-acting insulin and twice-daily biphasic insulin, but the group receiving thrice daily prandial rapid-acting insulin had a much higher risk of hypoglycemia with treatment than that given twice-daily biphasic insulin. However, a subsequent study by the same group added a second type of insulin if hyperglycemia became unacceptable during the first year of the study16. The addition of basal insulin to the group receiving thrice-daily prandial insulin therapy produced a dramatic decrease in the frequency of hypoglycemia, suggesting that basal insulin could stabilize the effect of bolus insulin. These data were consistent with the differing frequencies of hypoglycemic episodes observed between PPT and PBTS patients in the present study.

The reason why only the PPT patients gained the weight was obscure. While we checked who gained bodyweight one-by-one, the patients whose BMI was originally more than 25 remarkably gained bodyweight in comparison with those who had a BMI less than 25. We might have to pay attention to bodyweight gain while we use PPT for obese patients.

In the present study, three patients in the PBTS group needed the addition of basal insulin to achieve the target for fasting blood glucose. Their clinical backgrounds (including fasting C-peptide, two of which were 1.1 and 2.0 ng/mL, respectively) were not different from those of the rest of the patients in the PBTS group, except for a lower BMI. Mean BMI of the patients in the PBTS group was 22.9, but that of the patients who needed basal insulin was 21.4 (21.2, 22.8 and 20.1, respectively).

The ratio of basal to bolus insulin is generally 1:1 in treatments for type 1 diabetes. This ratio might also be applicable to type 2 diabetes, because increasing this ratio without increasing the total daily insulin dose improved glycemic control in type 2 diabetes patients receiving basal–bolus therapy with glargine19,20. In these arguments, endogenous insulin secretion capacity might be important. Unfortunately, we did not examine the complete data of fasting serum C-peptide from which we are able to suspect endogenous insulin secretion. Mean fasting serum C-peptide immuno-reactivity levels of the patients who were examined in the present study were 1.7 ± 0.7 ng/mL in the PBTS group (8/16) and 1.7 ± 0.8 ng/mL in the PPT group (7/15), respectively. These data and mean BMI (about 23) might suggest that endogenous insulin secretion capacity, at least in a large part of the patients in the present study, was not so seriously damaged as it was in the patients described by Tamaki et al.20 Lispro 50/50 comprises 50% lispro insulin as bolus insulin and 50% neutral protamine lispro as basal insulin. This prefixed ratio of basal to bolus might enable good glycemic control with a single-insulin therapy without sulfonylureas.

Based on these results, we recommend PPT as a good candidate for initial insulin therapy for type 2 diabetes.

**ACKNOWLEDGEMENTS**

We appreciate the kind contribution of Mr Munenori Fukui and Ms Satsuki Azuma (Chiba Tokushukai Hospital, Chiba Japan). This clinical trial received financial support from Nippon Eli Lilly and Company. Nippon Eli Lilly and Company did not have any influence on the analysis and interpretation of data.

TH and RK have received grant support from Takeda and Nippon Eli Lilly. TH has also acted as a spokesperson for Nippon Eli Lilly and Sanofi Aventis. FI has received grant support from Nippon Eli Lilly. YF has received grant support from Takeda. All other authors declare no conflict of interest.

**REFERENCES**

1. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the
European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963–1972.

2. International Diabetes Federation, Clinical Guidelines Task Force. Global guide line for type 2 diabetes. International Diabetes Federation, Brussels, Belgium. 2005.

3. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005–2012.

4. Yki-Järvinen H, Dressler A, Ziemen M; the HOE 901/3002 Study Group. Less nocturnal hypoglycemia and better postdinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000; 23: 1130–1136.

5. Yki-Järvinen H. Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2002; 18: S77–S81.

6. Riddle MC, Rosenstock J, Gerich J; the Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26; 2003;080–3086.

7. Rosenstock J. Basal insulin supplementation in type 2 diabetes: refining the tactics. Am J Med 2004; 116: 105–165.

8. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care 2006; 29: 1269–1274.

9. Holman RR, Thorne K, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357: 1716–1730.

10. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008; 31: 173–175.

11. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009; 52: 17–30.

12. Kazda C, Hulstrunk H, Helsberg K, et al. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complications 2006; 20: 145–152.

13. Jacober SJ, Scism-Bacon JL, Zagar AJ; for the IONW Study Investigator. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naive patients with type 2 diabetes receiving oral antidiabetes agents. Diabetes Obes Metab 2006; 8: 448–455.

14. Ilag LL, Kerr L, Malone JK, Tan MH. Prandial premixed insulin analogue regimens versus basal insulin analogue regimen in the management of type 2 diabetes: an evidence-based comparison. Clin Ther 2007; 29: 1254–1270.

15. Robbins DC, Beisswenger PJ, Ceriello A, et al. Mealtime 50/50 basal + prandial analogue mixture with a basal insulin analogue, both plus metformin, in blood glucose levels in patients with type 2 diabetes: a multinational, 24- week, randomized, open-label, parallel-group comparison. Clin Ther 2007; 29: 2349–2364.

16. Ebato C, Shimizu T, Arakawa M, et al. Effect of sulfonylureas on switching to insulin therapy (twice-daily biphasic insulin aspart 30): Comparison of twice-daily biphasic insulin aspart 30 with or without glimepiride in type 2 diabetic patients poorly controlled with sub-maximal glimepiride. Diabetes Res Clin Pract 2009; 86: 31–36.

17. Rosenstock J, Scism-Bacon J, Ahmann AJ, et al. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents. Prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 2008; 31: 20–25.

18. Holman RR, Farmer AF, Davies MJ, et al. for the 4T study group. Three-year efficacy of complex insulin regimen in type 2 diabetes. N Engl J Med ORG 2009; 361: 1736–1747.

19. Yokoyama H, Tada J, Kamikawa F, et al. Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Res Clin Pract 2006; 73: 35–40.

20. Tamaki M, Shimizu T, Kanazawa A, et al. Effect of changes in basal/total daily insulin ratio in type 2 diabetes patients on intensive insulin therapy including insulin glargine (JUN-LAN Study 6). Diabetes Res Clin Pract 2008, doi:10.1016/j.diabres.2008.03.021.